EP0904082A4 - Combination therapy for reducing the risks associated with cardiovascular disease - Google Patents
Combination therapy for reducing the risks associated with cardiovascular diseaseInfo
- Publication number
- EP0904082A4 EP0904082A4 EP97918595A EP97918595A EP0904082A4 EP 0904082 A4 EP0904082 A4 EP 0904082A4 EP 97918595 A EP97918595 A EP 97918595A EP 97918595 A EP97918595 A EP 97918595A EP 0904082 A4 EP0904082 A4 EP 0904082A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- reducing
- combination therapy
- cardiovascular disease
- risks associated
- risks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1568996P | 1996-04-17 | 1996-04-17 | |
US15689P | 1996-04-17 | ||
GB9612082 | 1996-06-10 | ||
GBGB9612082.9A GB9612082D0 (en) | 1996-06-10 | 1996-06-10 | Combination therapy for reducing the risks associated with cardiovascular disease |
US2097796P | 1996-06-24 | 1996-06-24 | |
US20977P | 1996-06-24 | ||
GBGB9616804.2A GB9616804D0 (en) | 1996-08-09 | 1996-08-09 | Combination therapy for reducing the risks associated with cardiovascular disease |
GB9616804 | 1996-08-09 | ||
PCT/US1997/006127 WO1997038694A1 (en) | 1996-04-17 | 1997-04-14 | Combination therapy for reducing the risks associated with cardiovascular disease |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0904082A1 EP0904082A1 (en) | 1999-03-31 |
EP0904082A4 true EP0904082A4 (en) | 2001-09-26 |
Family
ID=27451457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97918595A Ceased EP0904082A4 (en) | 1996-04-17 | 1997-04-14 | Combination therapy for reducing the risks associated with cardiovascular disease |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0904082A4 (en) |
JP (1) | JP2000508659A (en) |
AU (1) | AU732465B2 (en) |
CA (1) | CA2251972A1 (en) |
WO (1) | WO1997038694A1 (en) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0946178A4 (en) * | 1996-09-18 | 2003-05-07 | Merck & Co Inc | Combination therapy for reducing the risks associated with cardiovascular disease |
AU9454098A (en) * | 1997-09-24 | 1999-04-12 | Nova Molecular, Inc. | Methods for increasing apoe levels for the treatment of neurodegenerative disease |
PL343851A1 (en) * | 1997-12-12 | 2001-09-10 | Warner Lambert Co | Antihyperlipidemic statin-lp(a) inhibitor combinations |
US6235311B1 (en) * | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
GB2336534A (en) | 1998-04-24 | 1999-10-27 | Alec James Coppen | Anti-depressant - Folic Acid Combination |
AR030414A1 (en) * | 2000-04-03 | 2003-08-20 | Astrazeneca Ab | PHARMACEUTICAL COMBINATION THAT INCLUDES A BLOCKING BETA AND A REDUCED HMG-COA INHIBITOR, PHARMACEUTICAL FORMULATION, TRANSPORTABLE PARTS EQUIPMENT, USE OF THIS COMBINATION AND THIS FORMULATION TO PREPARE MEDICATIONS |
DK1272220T4 (en) * | 2000-04-10 | 2016-11-28 | Nicholas John Wald | Cardiovascular disease prevention formulation |
GB2361185A (en) | 2000-04-10 | 2001-10-17 | Nicholas J Wald | Pharmaceutical formulation for the prevention of cardiovascular disease |
SE0002354D0 (en) * | 2000-06-22 | 2000-06-22 | Astrazeneca Ab | New formulation |
US6916849B2 (en) | 2000-10-23 | 2005-07-12 | Sankyo Company, Limited | Compositions for improving lipid content in the blood |
AU2001295991A1 (en) * | 2000-10-23 | 2002-05-06 | Sankyo Company Limited | Compositions for improving lipids in blood |
AU2002211005A1 (en) | 2000-11-07 | 2002-05-21 | Sankyo Company Limited | Lipid peroxide-lowering compositions |
CA2427618A1 (en) * | 2000-11-29 | 2002-06-06 | Smithkline Beecham Corporation | Composition containing statins and calcium for improved cardiovascular health |
AU2002221131A1 (en) * | 2000-12-14 | 2002-06-24 | Sankyo Company Limited | Blood lipid ameliorant composition |
US7037934B2 (en) | 2000-12-14 | 2006-05-02 | Sankyo Company, Limited | Blood lipid ameliorant composition |
CA2430764A1 (en) * | 2000-12-14 | 2002-06-20 | Sankyo Company, Limited | Blood lipid ameliorant composition |
TWI284529B (en) * | 2000-12-18 | 2007-08-01 | Sankyo Co | A composition for lowering triglyceride |
ES2274013T3 (en) * | 2001-01-26 | 2007-05-16 | Schering Corporation | RECEIVER ACTIVATOR (S) COMBINATIONS ACTIVATED BY THE PROOFISER OF PEROXISOMES (PPAR) AND INHIBITOR (S) M OF THE ABSORPTION OF STELORS AND TREATMENTS FOR VASCULAR DISORDERS. |
AU2003281176A1 (en) * | 2002-07-11 | 2004-02-02 | Sankyo Company, Limited | Medicinal composition for mitigating blood lipid or lowering blood homocystein |
JP4611622B2 (en) * | 2002-07-11 | 2011-01-12 | 第一三共株式会社 | Pharmaceutical composition for improving blood lipid or reducing blood homocysteine |
AR040588A1 (en) | 2002-07-26 | 2005-04-13 | Schering Corp | PHARMACEUTICAL FORMULATION INCLUDING AN INHIBITOR OF CHOLESTEROL ABSORPTION AND AN INHIBITOR OF A HMGCO TO REDUCTASE |
JP4607436B2 (en) * | 2002-08-02 | 2011-01-05 | 第一三共株式会社 | Pharmaceutical composition containing an HMG-CoA reductase inhibitor |
WO2004012740A1 (en) * | 2002-08-02 | 2004-02-12 | Sankyo Company, Limited | MEDICINAL COMPOSITION CONTAINING HMG-CoA REDUCTASE INHIBITOR |
AU2004305154A1 (en) * | 2003-12-23 | 2005-07-07 | Medicure International Inc. | Combination therapies employing a composition comprising a HMG CoA reductase inhibitor and a vitamin B6 related compound |
DK1732605T3 (en) * | 2004-03-29 | 2019-06-11 | Wyeth Llc | Multi-vitamin and mineral supplements |
US7375112B2 (en) * | 2005-01-05 | 2008-05-20 | Medicure International Inc. | Compounds and methods for regulating triglyceride levels |
CA2664421A1 (en) * | 2006-09-22 | 2008-03-27 | Braincells, Inc. | Hmg coa reductase mediated modulation of neurogenesis |
EP2810644A1 (en) * | 2013-06-06 | 2014-12-10 | Ferrer Internacional, S.A. | Oral formulation for the treatment of cardiovascular diseases |
JP6443935B2 (en) * | 2013-07-26 | 2018-12-26 | 学校法人 久留米大学 | Combination of aspirin and folic acid for the treatment or prevention of arteriosclerosis |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5084482A (en) * | 1990-04-10 | 1992-01-28 | The Lithox Corporation | Methods for inhibiting inflammatory ischemic, thrombotic and cholesterolemic disease response with methionine compounds |
DE4326698A1 (en) * | 1993-08-09 | 1995-03-09 | Puetter Medice Chem Pharm | Use of a combination of folic acid, vitamin B6 and vitamin B12 for the prophylaxis and therapy of arteriosclerosis |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3895107A (en) * | 1970-04-15 | 1975-07-15 | Morrison L M | CSA and CSC in man and mammals to inhibit atherosclerosis and the recurrence of cardiovascular incidents in atherosclerotic mammals |
US5631401A (en) * | 1994-02-09 | 1997-05-20 | Abbott Laboratories | Inhibitors of protein farnesyltransferase and squalene synthase |
-
1997
- 1997-04-14 JP JP9537264A patent/JP2000508659A/en not_active Ceased
- 1997-04-14 WO PCT/US1997/006127 patent/WO1997038694A1/en not_active Application Discontinuation
- 1997-04-14 EP EP97918595A patent/EP0904082A4/en not_active Ceased
- 1997-04-14 AU AU26665/97A patent/AU732465B2/en not_active Ceased
- 1997-04-14 CA CA002251972A patent/CA2251972A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5084482A (en) * | 1990-04-10 | 1992-01-28 | The Lithox Corporation | Methods for inhibiting inflammatory ischemic, thrombotic and cholesterolemic disease response with methionine compounds |
DE4326698A1 (en) * | 1993-08-09 | 1995-03-09 | Puetter Medice Chem Pharm | Use of a combination of folic acid, vitamin B6 and vitamin B12 for the prophylaxis and therapy of arteriosclerosis |
Non-Patent Citations (9)
Title |
---|
"The Merck Manual of Diagnosis and Therapy", 1992, XP002170578 * |
BERG VAN DEN M ET AL: "COMBINED VITAMIN B6 PLUS FOLIC ACID THERAPY IN YOUNG PATIENTS WITH ARTERIOSCLEROSIS AND HYPERHOMOCYSTEINEMIA", JOURNAL OF VASCULAR SURGERY,US,ST. LOUIS, MO, vol. 20, no. 6, December 1994 (1994-12-01), pages 933 - 940, XP000853837, ISSN: 0741-5214 * |
BOUSHEY C. ET AL.: "A quantitative assessment of plasma homocysteine as a risk factor for vascular disease", JAMA, vol. 274, no. 13, 4 October 1995 (1995-10-04), pages 1049 - 1057, XP001005592 * |
DOBS A. ET AL.: "Lipid-lowering diets in patients, a new HMG-CoA reductase inhibitor: compliance and adequacy", AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 54, no. 4, October 1991 (1991-10-01), pages 696-700, XP001006920 * |
FEHER M D ET AL: "LONG-TERM SAFETY OF STATIN-FIBRATE COMBINATION TREATMENT IN THE MANAGEMENT OF HYPERCHOLESTEROLAEMIA IN PATIENTS WITH CORONARY ARTERY DISEASE", BRITISH HEART JOURNAL,BRITISH MEDICAL ASSOCIATION, LONDON,GB, vol. 74, no. 1, 1995, pages 14 - 17, XP000925445, ISSN: 0007-0769 * |
FROHLICH J J: "LIPOPROTEINS AND HOMOCYST(E)INE AS RISK FACTORS FOR ATHEROSCLEROSIS:ASSESSMENT AND TREATMENT", CANADIAN JOURNAL OF CARDIOLOGY,XX,PULSUS GROUP, INC, vol. 11, no. SUPPL. C, 1995, pages 18C - 23C, XP000910760, ISSN: 0828-282X * |
MAYER E L ET AL: "HOMOCYSTEINE AND CORONARY ATHEROSCLEROSIS", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY,XX,XX, vol. 27, no. 3, 1 March 1996 (1996-03-01), pages 517 - 527, XP000990693, ISSN: 0735-1097 * |
See also references of WO9738694A1 * |
TONSTAD S: "Low dose colestipol in adolescents with familial hypercholesterolaemia", ARCHIVES OF DISEASE IN CHILDHOOD, vol. 74, no. 2, February 1996 (1996-02-01), pages 157 - 160, XP001000237 * |
Also Published As
Publication number | Publication date |
---|---|
EP0904082A1 (en) | 1999-03-31 |
CA2251972A1 (en) | 1997-10-23 |
JP2000508659A (en) | 2000-07-11 |
AU2666597A (en) | 1997-11-07 |
WO1997038694A1 (en) | 1997-10-23 |
AU732465B2 (en) | 2001-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0904082A4 (en) | Combination therapy for reducing the risks associated with cardiovascular disease | |
EP0946178A4 (en) | Combination therapy for reducing the risks associated with cardiovascular disease | |
EG24678A (en) | Combination therapy | |
EP0879279A4 (en) | Diabetes therapy | |
AP2002002661A0 (en) | Combination therapy for oesteoporosis | |
ZA987843B (en) | Combination therapy. | |
IL127306A0 (en) | Combination therapy | |
EP1024696A4 (en) | Combination therapy for reducing the risks associated with cardio- and cerebrovascular disease | |
GB9601062D0 (en) | The updrifter | |
GB9421930D0 (en) | The barpress | |
GB9621970D0 (en) | Combination therapy for reducing the risks associated with cardiovascular disease | |
GB9616804D0 (en) | Combination therapy for reducing the risks associated with cardiovascular disease | |
GB9612082D0 (en) | Combination therapy for reducing the risks associated with cardiovascular disease | |
GB9603545D0 (en) | The spraymate | |
ZA977005B (en) | Therapeutic uses | |
GB9617526D0 (en) | The hand shield | |
EG21150A (en) | The egtptian lithotriptor k h j | |
GB9605466D0 (en) | Therapy | |
GB9605525D0 (en) | Therapy | |
GB9602510D0 (en) | The easythrow fetchball | |
GB9602199D0 (en) | The seducterlens | |
GB9613369D0 (en) | The Susean | |
GB9613295D0 (en) | The transcendulator | |
GB9611121D0 (en) | The mirrormaker | |
GB9626734D0 (en) | The jetlift |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19981117 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7A 61K 31/53 A, 7A 61K 31/35 B, 7A 61K 31/505 B, 7A 61P 3/06 B, 7A 61P 9/10 B |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20010814 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20020516 |
|
TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20051219 |